All In Biotech

Drug Trial Radar · NCT02448797

Icotinib as Adjuvant Therapy Compared With Standard Chemotherapy in Stage II-IIIA NSCLC With EGFR-mutation

Icotinib as Adjuvant Therapy Compared With Standard Chemotherapy in Stage II-IIIA Non-small Cell Lung Cancer With EGFR-mutation: a Randomized, Positive-controlled, Phase 3 Study (EVIDENCE, CCTC-1501)

Last checked: Nov 19, 2026Latest source record: Jul 20, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. Randomized with 320 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

320

Planned (sponsor's estimate)

Start

Jun 8, 2015

Primary completion

Jun 30, 2022

Study completion Dec 2023

Sponsor

Sponsor type
Industry
First posted
May 19, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Adjuvant therapy has been proved effective in treating earlier stage or less advanced non-small-cell lung cancer. This study is designed to evaluate the efficacy of icotinib as adjuvant therapy in treating stage II-IIIA non-small cell lung cancer patients with EGFR mutation. The primary endpoint is disease-free survival.

Conditions

  • Non-small Cell Lung Cancer

Interventions

  • IcotinibDrug

    125 mg three times daily (375 mg per day) orally for two years.

  • ChemotherapyDrug

    Vinorelbine 25 mg/m\^2, intravenously guttae, day 1 and day 8, 21 days/cycle, 4 cycles, cisplatin 75 mg/m\^2, intravenously guttae, day 1, 21 days/cycle, 4 cycles. For adenocarcinoma: pemetrexed (500 mg/m\^2, day 1)/cisplatin (75 mg/m\^2, day 1) for 4 cycles.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. disease free survivalTime frame: 48 months

Locations

8 sites in 1 country. Site status is shown where the registry gives one.

  • 307 Hospital of PLA

    Beijing, Beijing Municipality, China

  • Fujian Provincal Cancer Hospital

    Fuzhou, Fujian, China

  • The First Affiliated Hospital Of Guangzhou Medical Collage

    Guangzhou, Guangdong, China

  • Shenzhen People's Hospital

    Shenzhen, Guangdong, China

  • The First Hospital of China Medical University

    Shenyang, Liaoning, China

  • First Affiliated Hospital of China Medical University

    Shenyang, Liaoning, China

  • Shanghai Pulmonary Hospital

    Shanghai, Shanghai Municipality, China

  • The First Affiliated Hospital of Medical School of Zhejiang University

    Hangzhou, Zhejiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.